Endovascular therapy improves left ventricular diastolic function in heart failure with preserved ejection fraction
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
Medscape1d
Pharmacologic Management of Heart Failure with Preserved Ejection Fraction
An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...
Pharmabiz1h
EMA committee recommends Novo Nordisk’s Wegovy label update to reflect reduced heart failure symptoms and improved physical function
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...
The New England Journal of Medicine20d
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed.
Medscape10d
Finerenone Reduces T2D Onset by 25% in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...
Too Old to Operate14d
FINEARTS-HF: Finerenone Helps Across Ejection Fraction Spectrum
Finerenone has been shown to significantly reduce the risk for cardiovascular death in patients with heart failure in results from the FINEARTS-HF trial.
CNN20d
Kidney disease medication found to reduce risk of cardiovascular death in certain heart failure patients in new study
The medication, finerenone, could be an effective therapy in people with heart failure who have mildly reduced or preserved ejection fraction, suggests the study, published Sunday in the New Engla ...
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study
Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, ...
PipelineReview.com1d
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...